Skip to main content
AmigoFish

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

From Pharmaceutical Executive · · 3 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

Back to Pharmaceutical Executive · Report a problem